Develops gene-editing drug candidates for patients with hereditary angioedema and transthyretin amyloidosis.
10-K for FY2025, filed Feb 26, 2026
Partners pay Intellia through upfront license fees, research funding, shared-cost payments and development, regulatory and commercial milestones; it may also receive a share of sales of licensed products.
10-K for FY2025, filed Feb 26, 2026Our revenue consists of collaboration revenue, including amounts recognized related to upfront technology access payments for licenses…View ↗
As of December 31, 2025, the Company’s revenue recognized is solely related to collaboration agreements with third parties which are either…View ↗
Milestone payments: At the inception of each arrangement that includes development milestone payments, the Company evaluates the…View ↗
Royalties: For arrangements that include sales-based royalties, including milestone payments based on levels of sales, if the license is…View ↗
$67.7M
10-K for FY2025, filed Feb 26, 2026
$67.7M ↗
Revenue comes from collaboration partners such as Regeneron, which work with Intellia under licensing and research agreements.
10-K for FY2025, filed Feb 26, 2026In order to treat—and potentially cure—a broader range of severe diseases, we and our collaboration partners are advancing the development…View ↗
Collaborate with partners to expand the reach of our technology and maximize our return on investment. Since our inception, collaborations…View ↗
As of December 31, 2025, the Company’s revenue recognized is solely related to collaboration agreements with third parties which are either…View ↗
No. It lost $412.7M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$127.5MView ↗
8-K, filed Sep 8, 2026
Also on September 8, 2026, the Company announced that the U.S. Food and Drug Administration (“FDA”) has accepted the Biologics License…View ↗
Growing. Revenue grew 2.0x in 4 years, from $33.1M in FY2021 to $67.7M in FY2025, about 20% a year.
Moving toward commercialization
The older report describes a broad in vivo and ex vivo development pipeline; the latest report emphasizes launch preparation for lonvo-z and a U.S.-focused commercial and medical affairs team.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 26, 2026
Competes with ADARx Therapeutics, Argo Biopharmaceutical, BioCryst Pharmaceuticals, CSL, Gritgen Therapeutics, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Pharming Group, Pharvaris, Takeda Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca Pharmaceuticals, BridgeBio Pharma, Bayer, Metagenomi Therapeutics, Novo Nordisk, Pfizer, and YolTech Therapeutics
10-K for FY2025, filed Feb 26, 2026Specific to our lonvo-z program, we are aware of other companies that are currently commercializing or developing products used to treat…View ↗
Loading...